Prosecution Insights
Last updated: November 04, 2026
Application No. 18/734,622

COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES

Non-Final OA §112
Filed
Jun 05, 2024
Examiner
JACKSON, SHAWQUIA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Theralase Technologies Inc.
OA Round
2 (Non-Final)
78%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1439 granted / 1843 resolved
+18.1% vs TC avg
Minimal -4% lift
Without
With
+-3.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
46 currently pending
Career history
1891
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
50.6%
+10.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1843 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-17 are pending. Applicants have amended claims 1, 10, 12 and 16 in the amendment filed on August 20, 2026. The claims 1-4, 8-10 are rejected, claims 5-7 are objected and claims 11-17 are considered allowable in this Office Action. I. Response to Remarks Applicants’ amendment, filed on August 20, 2026, has overcome the rejection of claims 1-17 under 35 USC 112(b) as being indefinite for the term “including”; the rejection of claims 10 and 16 under 35 USC 112(b) as being indefinite for the term “comprises”; and the objection of claims 10 and 16 for containing the phrase “and pharmaceutically acceptable salts” and not having the term “and” in between the last two structures listed in the claims. The above rejections and objections have been withdrawn. II. Information Disclosure Statement The information disclosure statement (IDS) submitted on August 20, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. III. Rejection(s) Claim Rejections - 35 USC § 112 (a) The following is a quotation of the first paragraph of 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-4, 8-10 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The limitation “at least one active pharmaceutical ingredient (API)” has not been clearly defined in the specification so that one of ordinary skill in the art would know what active pharmaceutical ingredients are included and/or excluded. Applicants’ specification has provided support and written description of the API being selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir but has not provided written description of the API being any active agent in the combination. The API should be limited to what Applicants have clear support and description for in the specification to overcome the rejection. IV. Objections Dependent Claim Objections Dependent Claims 5-7 are also objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim. V. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is (571)272-9043. The examiner can normally be reached on M-F 7AM-4PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached on (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jun 05, 2024
Application Filed
May 20, 2026
Non-Final Rejection mailed — §112
Aug 20, 2026
Response Filed
Oct 20, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774305
NOVEL CYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THE USE OF SAID CYCLIC COMPOUNDS IN COSMETIC PREPARATIONS
3y 5m to grant Granted Oct 27, 2026
Patent 12767649
PROCESS FOR THE SYNTHESIS OF 5-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)FURAN-2-CARBALDEHYDE AND OF NITRONES FROM 5-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)FURAN-2-CARBALDEHYDE
2y 4m to grant Granted Oct 20, 2026
Patent 12759978
Novel Psilocin Analog Compositions And Methods of Synthesizing The Same
3y 5m to grant Granted Oct 13, 2026
Patent 12758559
RXFP1 AGONISTS
2y 6m to grant Granted Oct 13, 2026
Patent 12753183
1,5-DISUBSTITUTED 1,2,3-TRIAZOLES ARE INHIBITORS OF RAC/CDC42 GTPASES
2y 7m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-3.5%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1843 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month